Matthew Keller
Stock Analyst at HC Wainwright & Co.
(n/a)
# 4,693
Out of 5,147 analysts
12
Total ratings
9.09%
Success rate
-34.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.14 | +1,128.07% | 2 | Feb 10, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $6 → $24 | $3.11 | +671.70% | 2 | Jan 27, 2026 | |
| IFRX InflaRx | Reiterates: Buy | $6 | $0.92 | +552.17% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $2.98 | +269.13% | 2 | Dec 17, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $30.50 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $1.50 | +1,966.67% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $8.24 | +118.45% | 1 | Aug 26, 2025 |
Phio Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $14
Current: $1.14
Upside: +1,128.07%
60 Degrees Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $6 → $24
Current: $3.11
Upside: +671.70%
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $0.92
Upside: +552.17%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $2.98
Upside: +269.13%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $30.50
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $1.50
Upside: +1,966.67%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $8.24
Upside: +118.45%